Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein b genes

Circulation: Cardiovascular Genetics

Volumn 4, Issue 4, 2011, Pages 413-417

  Huijgen, Roeland ^a   Vissers, Maud N ^a   Kindt, Iris ^b   Trip, Mieke D ^a   De Groot, Eric ^a   Kastelein, John J P ^a   Hutten, Barbara A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Foundation for the Identification of Persons with Inherited Hypercholesterolemia   (Netherlands)

Author keywords

Arteriosclerosis; Diagnosis; Familial hypercholesterolemia; Genetic screening; Hyperlipoproteinemia type II; Phenotype

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOGRAPHY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; RECEPTORS, LDL; YOUNG ADULT;

EID: 80052734868     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.110.959239     Document Type: Article

References (26)

1. Goldstein JL, Hobbs HH, Brown MS. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001.
2. Wilson JM, Jungner YG. [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam. 1968;65:281-393.
3. Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Hutten BA. Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther. 2008;6:567-581.
4. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.
5. Defesche JC. Familial hypercholesterolemia. In: Betteridge DJ, ed. Lipids and Vascular Disease. London, UK: Martin Dunitz Ltd; 2000:65-76.
6. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357:165-168. (Pubitemid 32108086)
7. Huijgen R, Kindt I, Verhoeven SB, Sijbrands EJ, Vissers MN, Kastelein JJ, Hutten BA. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS ONE. 2010;5:e9220.
8. Huijgen R, Kindt I, Fouchier SW, Defesche JC, Hutten BA, Kastelein JJ, Vissers MN. Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia. Hum Mutat. 2010;31:752-760.
9. Cobbaert C, Boerma GJ, Lindemans J. Evaluation of the Cholestech L.D.X. desktop analyser for cholesterol, HDL-cholesterol, and triacylglycerols in heparinized venous blood. Eur J Clin Chem Clin Biochem. 1994;32:391-394.
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
11. Gotto AM Jr, Bierman EL, Connor WE, Ford CH, Frantz ID Jr, Glueck CJ, Grundy SM, Little JA. Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriocslerosis. Circulation. 1984;69:1065A-1090A. (Pubitemid 14137303)
12. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, Kastelein JJ. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004;109:III33-III38. (Pubitemid 38786441)
13. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJ, Kastelein JJ. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004;363: 369-370. (Pubitemid 38169546)
14. Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation. 2005;112:3168-3173. (Pubitemid 43113445)
15. Tonstad S, Joakimsen O, Stensland-Bugge E, Ose L, Bonaa KH, Leren TP. Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects. Eur J Clin Invest. 1998;28:971-979. (Pubitemid 29050129)
16. Junyent M, Cofan M, Nunez I, Gilabert R, Zambon D, Ros E. Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26: 1107-1113. (Pubitemid 43732119)
17. Bertolini S, Pisciotta L, Di Scala L, Langheim S, Bellocchio A, Masturzo P, Cantafora A, Martini S, Averna M, Pes G, Stefanutti C, Calandra S. Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis. 2004;174:57-65. (Pubitemid 38595440)
18. Vuorio AF, Turtola H, Piilahti KM, Repo P, Kanninen T, Kontula K. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arterioscler Thromb Vasc Biol. 1997; 17:3127-3138. (Pubitemid 28016068)
19. Abifadel M, Rabes JP, Jambart S, Halaby G, Gannage-Yared MH, Sarkis A, Beaino G, Varret M, Salem N, Corbani S, Aydenian H, Junien C, Munnich A, Boileau C. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum Mutat. 2009.
20. Fouchier SW, Huijgen R, Vis K, Defesche JC, Kastelein JJP. Identification of APOB and PCSK9 mutations causing a non-autosomal dominant hypercholesterolemia (ADH) phenotype in molecular diagnosed ADH patients [abstract]. Atherosclerosis. 2009;10(suppl):P870.
21. Van der Graaf A, Fouchier SW, Vissers MN, Defesche JC, Wiegman A, Sankatsing RR, Hutten BA, Trip MD, Kastelein JJ. Familial defective apolipoprotein B and familial hypobetalipoproteinemia in one family: two neutralizing mutations. Ann Intern Med. 2008;148:712-714. (Pubitemid 351669126)
22. Pimstone SN, Sun XM, du Souich C, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol. 1998;18:309-315. (Pubitemid 28277610)
23. Tonstad S, Leren TP, Sivertsen M, Ose L. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway. Arterioscler Thromb Vasc Biol. 1995;15:1009-1014.
24. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577-581. (Pubitemid 32179609)
25. Vergeer M, Zhou R, Bots ML, Duivenvoorden R, Koglin J, Akdim F, Mitchel YB, Huijgen R, Sapre A, de Groot E, Sijbrands EJ, Pasternak RC, Gagne C, Marais AD, Ballantyne CM, Isaacsohn JL, Stalenhoef AF, Kastelein JJ. Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies. Circ Cardiovasc Imaging. 2010;3:398-404.
26. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292:331-337. (Pubitemid 38944256)